Suppression of agrin has been shown to boost CD8+ T-cell recruitment in BC models and block tumour progression, and a new trial determined that agrin in the BC model was acting as an important component of structural ECM, modulating the immune microenvironment, and may even be a new therapeutic opportunity in BC [119]. The gene discussed is CD8A; the disease is neoplasm.